Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Inclusion Criteria: * Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice * Be female and ≥18 and ≤75 years of age * Be ambulatory and have ECOG performance stastus of ≤1 * Have histological confirmed breast cancer,and the speciman confirmed ER negative,PR negatiev, and HER-2 negative by immunochemistry technich of Fudan cancer hospital. * Locally advanced or metastastic breast cancer who didn't receive first-line chemotherapy. No matter whether the patient has received anthracyclin or taxane treatment as neo-adjuvant or adjuvant treatment. * Have at least one target lesion according to the RECIST criteria. Exclusion criteria: * Preganant or lactating women * Advaced patient has received one or more chemotherapies * Chemotherapy within four weeks preceding treatment start * ECOG ≥ 2 * Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy * Participation in any investigational drug study within 4 weeks preceeding treatment start * Evidence of CNS metastasis * History of another malignacy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer * Abnormal laboratory values: hemoglobin \< 8. 0g/dl, neutrophil\< 1.5×109/L, platelet\< 100×109/L. * serum creatine \> upper limit of normal (ULN) * serum bilirubin \> ULN * ALT and AST \>5×ULN * AKP \>5×ULN * Serious uncontrolled intercurrence infection * Life expectancy of less than 3 months